ArticleBMC cancer2026
NAV-005, a high-affinity MUC16/CA125 antagonist for the treatment of humoral immunosuppressed cancers.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to develop a high-affinity therapeutic antagonist to overcome tumor-produced MUC16/CA125 (herein CA125) mediated immunosuppression of anticancer therapeutic antibodies and antibody-drug conjugates (ADCs). The goal was to generate an antagonist that blocks CA125 binding to IgG1 antibodies, restores antibody interaction with CD16a Fc-γ-activating receptors (herein CD16a) and C1q protein, and re-enables maximal antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against cancer cells. Since CA125 binding to ADCs impairs its cytotoxicity by reducing ADC internalization, the antagonist was further designed to restore maximal ADC activity. Achieving these aims supports the clinical development of CA125 antagonists for treating cancers marked by humoral immunosuppression.
methodsHuman IgG1 Fc fusion proteins with varying mesothelin binding domain (MBD) motifs were engineered and tested for high-affinity CA125 binding. Antagonist efficacy was assessed by measuring restoration of CD16a and C1q binding to IgG1 antibodies suppressed by CA125. ADC internalization assays evaluated the effect of CA125 and antagonists on ADC uptake. Cellular assays, including Jurkat-CD16a reporter and PBMC-based ADCC assays, measured restoration of antibody-CD16a mediated immune effector cell killing of target cells. Cytotoxicity assays assessed CDC and ADC mediated cell killing.
resultsNAV-005 (MBD2-Fc), a lead antagonist, bound CA125 with high affinity and blocked its binding to IgG1-type antibodies. NAV-005 reversed CA125-induced antibody immunosuppression, thereby restoring IgG1 mediated ADCC and CDC by preventing CA125-IgG1 interaction. NAV-005 also prevented CA125-ADC cell surface interactions, thereby restoring maximal ADC internalization and target cell killing.
conclusionTumor-produced CA125 impairs therapeutic antibody and ADC efficacy via humoral immunosuppression. NAV-005 counteracts this effect, restoring antitumor activity of antibodies and ADCs in CA125-expressing cancers. These results support the continued development of CA125 antagonists as adjuncts to antibody-based cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.